Ardelyx Inc. buy melinda
Summary
This prediction ended on 13.08.18 with a price of €3.79. The price of Ardelyx Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -25.66%. melinda has 50% into this predictionArdelyx, Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative medicines aimed at treating kidney and cardiovascular diseases. The company uses a unique approach to drug discovery, developing therapeutics that target ion channels and transporters, which play a critical role in regulating activities in the body. Ardelyx's lead product candidate, tenapanor, is being studied for the treatment of conditions such as hyperphosphatemia in patients with chronic kidney disease, irritable bowel syndrome with constipation, and diverticulosis. The company is listed on the NASDAQ exchange under the ticker symbol ARDX.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Ardelyx Inc. | -2.473% | -2.473% | 23.214% | 352.459% |
iShares Core DAX® | 1.663% | 6.945% | 18.807% | 17.549% |
iShares Nasdaq 100 | 1.261% | 4.883% | 23.667% | 36.206% |
iShares Nikkei 225® | 0.654% | 10.007% | 15.047% | 9.552% |
iShares S&P 500 | 1.403% | 4.350% | 23.305% | 38.641% |
Comments by melinda for this prediction
In the thread Ardelyx Inc. diskutieren
Biotechnologie und Medizintechnik SecteurRecherche Agenda 15/02 | 20.00 Uhr Präsentation
im Magen - Darm - Trakt wirkt Herz- und Nierenerkrankungen, Magen - Darm- und Stoffwechsel zu behandeln. Ardelyx, Inc. betreibt als biopharmazeutisches Unternehmen in der klinischen Phase.
Es ist klein minimal systemisch System Molekül auf die Entdeckung, Entwicklung und Vermarktung von Therapien gewidmet , die ausschließlich im Magen - Darm - Trakt wirken zu Magen - Darm - Erkrankungen und Herz-Nieren zu behandeln.
Die Produkte des Unternehmens umfassen Tenapanor, RDX002, RDX009 und RDX013.
Ardelyx wurde von Dominique Charmot, Peter G. Schultz und Herr Jean Frechet 17. Oktober 2007 gegründet und befindet sich in Fremont, CA, USA hat seinen Hauptsitz
Anzahl der Mitarbeiter: 93 Personen.